Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients.

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up / Palandri, F; Castagnetti, F; Testoni, N; Luatti, S; Marzocchi, G; Bassi, S; Breccia, M; Alimena, Giuliana; Pungolino, E; REGE CAMBRIN, G; Varaldo, R; Miglino, M; Specchia, G; Zuffa, E; Ferrara, F; Bocchia, M; Saglio, G; Pane, F; Alberti, D; Martinelli, Giovanni; Baccarani, M; Rosti, G; GIMEMA WORKING PARTY ON CHRONIC MYELOID, Leukemia. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 93:(2008), pp. 1792-1796. [10.3324/haematol.13068]

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

BRECCIA M;ALIMENA, Giuliana;MARTINELLI, GIOVANNI;
2008

Abstract

Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients.
2008
chronic myeloid leukemia, blast crisis, imatinib, outcome, long-term
01 Pubblicazione su rivista::01a Articolo in rivista
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up / Palandri, F; Castagnetti, F; Testoni, N; Luatti, S; Marzocchi, G; Bassi, S; Breccia, M; Alimena, Giuliana; Pungolino, E; REGE CAMBRIN, G; Varaldo, R; Miglino, M; Specchia, G; Zuffa, E; Ferrara, F; Bocchia, M; Saglio, G; Pane, F; Alberti, D; Martinelli, Giovanni; Baccarani, M; Rosti, G; GIMEMA WORKING PARTY ON CHRONIC MYELOID, Leukemia. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 93:(2008), pp. 1792-1796. [10.3324/haematol.13068]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/32244
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 78
  • ???jsp.display-item.citation.isi??? 76
social impact